Other

Drexel University

Ophthalmic Research Corporation

Image Optical Corporation

Cleo Cosmetic and Pharmaceutical Company, LLC

Designs for Vision, Inc.

David B Soll

Richard E Feinbloom

Ihab L Kamel

Sol E Harrison

Stephen J Failla

Inez Ruiz-White

Rolf A Schmidt

Richard C Pauley

Teresita M Smith

Thomsen J Hansen

Inez A Ruiz-White

A viewfinder including a base member for removably mounting on an electronic device suitable for taking digital photographs, attachment means connected to said base member for coupling the base member to an electronic device, an open-ended housing disposed on the base member, and a sighting grid disposed adjacent an open end of the open-ended housing and method for using same is provided.

Viewfinder

A fixture and method is provided for in vitro storage of a cornea. The fixture includes a platform having a corneal-sceral rim receiving surface, a clamp having a mating surface for the cornel-scleral rim and handles. A locking mechanism is provided to secure a donor cornea between the clamp and platform. The combination cornea, platform and clamp are placed in a storage unit having a fluid preservation media. In one embodiment, the storage unit includes a vial having an optically clear closed end and an opened end. A lid is secured to the open end of the vial and engages the handles in order to stabilize the clamped cornea within the vial.

Apparatus and method for in vitro storage of a cornea

Camera view finder

A corneal storage solution which maintains cell density and cell viability of corneas stored in vitro for a period of greater than four days up to about two weeks is provided. The solution contains a buffered, balanced, nutrient and electrolyte aqueous solution, at least one colloidal osmotic agent, a phenolic antioxidant compound, a non-lactate-generating substrate, a thiol-containing compound, insulin, and at least one antibiotic. A method for in vitro storage and preservation of the viability of human corneal endothelial cells for subsequent use includes the steps of removing a cornea from an eye globe and placing the cornea in the above corneal storage solution.

Composition using HMW dextran and method for in vitro preservation of corneal tissues

Hyaluronic acid, a polymer found in the trabecular meshwork of the eye, has a polymeric structure that is broken down by the enzyme hyaluronidase. A method is provided for reducing elevated intraocular pressure in an eye of a patient, such as a patient suffering from glaucoma, by administering modified hyaluronidase to the surface of the eye as a drop, spray, ointment, sustained-release or non-sustained release unit, and allowing the hyaluronidase to remain within the anterior chamber of the eye. The hyaluronidase is modified to enhance penetration through the corneal barrier, and is administered in an amount effective to reduce an elevated intraocular pressure. The method thus reduces the elevated intraocular pressure in the eye of a glaucoma patient without undesirable side effects.

Method for treating elevated intraocular pressure, including glaucoma

Hyaluronic acid is commonly used as a spacer in eye surgeries such as cataract surgery, intraocular lens surgery, corneal transplant surgery and some types of glaucoma surgery. One common side effect of these surgical procedures is a postoperative rise in intraocular pressure which can be serious and can cause permanent loss of function of optic nerve fibers and, therefore, loss of visual field function as well as visual acuity function. Intraoperative and postoperative rises in intraocular pressure also occur in vitreous, retina and other posterior segment surgeries. Methods are provided for reducing the postoperative intraocular pressure in an eye to normal preoperative levels while maintaining the therapeutic effects of the hyaluronic acid. One method comprises anesthetizing the eye at the start of the surgical procedure, administering to the eye substantially concurrently amounts of hyaluronic acid and hyaluronidase and leaving the hyaluronic acid and hyaluronidase in the eye after the operative procedure.

Methods for reducing postoperative intraocular pressure

An illumination device for mounting on the head of a user including a frame having a cross member and a pair of rearwardly extending temple members attached to opposite ends of the cross member. At least one focusable light assembly is rotatably mounted to the frame and includes a light source for emitting light. The light assembly is adjustable by the user for varying the vergence and direction of the light emitted from the light source.

Illumination device for mounting on the head of a user

A necktie securing device for securing to a shirt front a necktie having a tail, an apron and a label, the label being attached to a rear surface of the apron, to a shirt front when the tail is disposed within an opening formed by the label and the apron, includes a first clip demountably attachable to the tail and having a first VELCRO material covered joining surface and a second clip demountably attachable to an overlapping edge of the shirt front and having a second joining surface covered by complementary VELCRO material, the second joining surface of the second clip being engageable with the first joining surface of the first clip.

Method of securing a necktie to a shirt front and device therefor

The present invention is a viewing assembly that can selectively create optical compound corrections in the images reflected from the viewing assembly. The viewing assembly includes a reflective surface coupled to a supporting body in such a manner that the reflective surface conforms to the contour of the supporting body. The contour of the supporting body is selectively altered by the viewer of the viewing assembly, thereby changing the shape of the reflective surface and creating desired optical corrections in the viewed reflected images.

Viewing assembly for producing an optically corrected reflected image

The present invention is a viewing assembly that can selectively create optical compound corrections in the images reflected from the viewing assembly. The viewing assembly includes a reflective surface coupled to a supporting body in such a manner that the reflective surface conforms to the contour of the supporting body. The contour of the supporting body can then be selectively altered by the viewer of the viewing assembly, thereby changing the shape of the reflective surface and creating desired optical corrections in the viewed reflected images.

A method of permanently modifying the surface of a substrate material so as to develop a microscopically smooth, biocompatible surface thereon comprises covalently grafting a biocompatible polymeric material to the surface of the substrate material by radio frequency plasma-induced grafting. The biocompatible polymeric material is preferably the same as the substrate material. In addition, a method of permanently modifying the surface of a substrate material comprises subjecting the substrate surface to radio frequency plasma sufficient to raise the temperature at the substrate material to just above the glass transition temperature (T.sub.g) of the substrate material for a time sufficient to produce a microscopically smooth, biocompatible surface on the substrate material. Further, a prosthesis used in mammals, including an intraocular lens, comprises a polymeric material core and a biocompatible polymeric material covalently grafted to the polymer core by radio frequency plasma induction.

Biocompatible, surface modified materials

The cells of the coverings and linings of internal human and animal tissues, organs and body cavities subject to trauma, such as surgery, may be protected against exfoliation or destruction by the topical application or injection of effective amounts of chondroitin sulfate prior to or during the trauma. Preferably, the chondroitin sulfate is used in physiological solutions in concentrations of about 40 to 55 weight percent, and may be used as a surgical irrigating solution. Intraarticular injection of such chondroitin sulfate solutions into human and animal joints having degenerative joint conditions protects the joint cells, reduces aseptic inflammation and/or prevents further degeneration of cartilage tissue. Solutions for preserving human and animal cells and tissues in vitro for later in vivo use have extended storage life when chondroitin sulfate is added to such storage solutions in effective amounts such as about 1 to 20 weight percent of the storage solution.

Protection of human and animal cells

The present invention includes methods of permanently modifying the surface of a substrate material so as to develop a microscopically smooth, biocompatible surface thereon. A portion of the substrate surface is first removed, as by etching, in a radio frequency plasma reactor using inert argon gas. A biocompatible polymeric material may be covalently grafted to the surface of the substrate material by radio frequency plasma-induced grafting. The biocompatible polymeric material is preferably the same as the substrate material but may be different. Alternatively, after etching, the surface of a substrate material may be subjected to radio frequency plasma sufficient to raise the temperature at the substrate surface to just above the glass transition temperature (T.sub.g) of the substrate material for a time sufficient to produce a microscopically smooth, biocompatible surface on the substrate material. Further, the present invention includes a prosthesis used in mammals, including an intraocular lens, having a polymeric material core and a biocompatible polymeric material covalently grafted to the polymer core by radio frequency plasma treatment.

Growing community of inventors

Rydal, PA, United States of America

David B Soll